ArticleInternational journal of molecular sciences2025
Electrochemically Reduced Graphene Oxide Covalently Bound Sensor for Paracetamol Voltammetric Determination.
Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A chitosan/rGO/FeRSC advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Designing a highly sensitive and efficient functionalized electrode for precise drug analysis remains a significant challenge. In this work, an electrochemical sensor based on a glassy carbon electrode (GCE) modified with phenyl diazonium salts (ph) and electrochemically reduced graphene oxide (ERGO), labeled GCE/ph/ERGO, was developed for the detection of paracetamol (PAR) in pharmaceutical matrices using square wave voltammetry (SWV). The modified electrode was characterized by scanning electron microscopy (SEM), electrochemical impedance spectroscopy (EIS), and cyclic voltammetry (CV). Compared to the bare GCE, the GCE/ph/ERGO sensor demonstrated significantly improved conductivity and anodic current peak for PAR over two orders of magnitude higher, indicating a substantial enhancement in electrochemical performance. Under optimized conditions, the developed sensor exhibited a low detection limit of 18.2 nM and a quantification limit of 60.6 nM. Precision studies yielded relative standard deviations (RSDs) below 8%. The sensor demonstrated excellent selectivity in the presence of common pharmaceutical excipients and high accuracy in the analysis of generic pharmaceutical formulations, with results comparable to those obtained by the HPLC technique. These findings confirm the sensor's reliability, stability, robustness, and suitability for routine analysis of PAR in pharmaceutical samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.